Halozyme Therapeutics reported $225.5M in EBITDA for its fiscal quarter ending in June of 2025.




Ebitda Change Date
Acadia Pharmaceuticals USD 35.31M 13.07M Jun/2025
Agios Pharmaceuticals USD -125797000 20.45M Jun/2025
Alnylam Pharmaceuticals USD 18.83M 13.65M Jun/2025
Amarin USD -16025000 714K Mar/2025
Amgen USD 3.6B 147M Jun/2025
Baxter International USD 325M 251M Mar/2025
Cytokinetics USD -153331000 16.67M Mar/2025
DBV Technologies USD -39036000 16.89M Jun/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Halozyme Therapeutics USD 225.5M 63.51M Jun/2025
Ionis Pharmaceuticals USD 150.23M 291.7M Jun/2025
MannKind USD 9.75M 17.66M Jun/2025
Pfizer USD 5.32B 889M Jun/2025
United Therapeutics USD 436.8M 34.2M Jun/2025